We have a robust and growing intellectual property estate covering our mRNAi GOLD™ platform, including all aspects of siRNA modification, delivery, construct design, specific drug products and their uses.
We have developed chemical modification patterns that enhance stability and improve activity
We have developed proprietary linkers, enabling the attachment of targeting ligands to the siRNA molecule
We attach the GalNAc ligand to our siRNA molecule at one or more different sites for highly targeted delivery to specific liver tissues/cells